Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary, Compliance Officer, KMP effective April 9, 2026
Cohance Lifesciences Limited has appointed Mr. Sisir K. Mishra as Company Secretary, Compliance Officer, and Key Managerial Personnel. The appointment is effective from April 9, 2026. Mr. Mishra brings over two decades of experience in corporate secretarial and governance roles.
The appointment of a Company Secretary and Compliance Officer is a standard corporate governance requirement and is unlikely to have a significant immediate impact on the company's operations or financial performance.
The announcement is a routine corporate action regarding the appointment of a key managerial personnel and does not contain any information that would suggest a positive or negative financial or strategic impact on the company.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced the appointment of Mr. Sisir K. Mishra as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) of the company. This decision was approved by the Board of Directors at their meeting held on Monday, March 30, 2026, based on the recommendation of the Nomination and Remuneration Committee.
Mr. Mishra's appointment will be effective from April 9, 2026. He is a Fellow Member of the Institute of Company Secretaries of India and holds an LL.M. from Osmania University. He brings over two decades of experience in corporate secretarial, legal, governance, CSR, and ESG functions across various sectors. His expertise includes board governance, regulatory interface, mergers, fundraising, IPO readiness, and compliance management systems. Previously, he served as Company Secretary with NCC Limited, Paradeep Phosphates Limited, Deccan Cements Limited, and KSK Group.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.